Journal of Dali University ›› 2024, Vol. 9 ›› Issue (2): 76-80.

Previous Articles     Next Articles

Distribution and Drug Resistance of Clinically Isolated Pathogenic Bacteria in Patients with Hematologic Tumors in a Hospital

Zhang Dingcai1, Xu Kai2, Xu Yu2, Yan Jinfang2, Li Tianli2, Cao Fang2*   

  1. (1.College of Pharmacy, Dali University, Dali, Yunnan 671000, China; 2.Department of Pharmacy, Southern Central Hospital of
    Yunnan Province, Gejiu, Yunnan 661199, China)
  • Received:2023-03-02 Revised:2023-03-29 Online:2024-02-15 Published:2024-02-24

Abstract: Objective: To analyze the distribution and drug resistance of clinically isolated pathogenic bacteria in patients with
hematologic tumors in a hospital, and to provide medication guidance for empirical treatment of these patients with co-infection.
Methods: Retrospective analysis was used to collect the distribution and drug resistance of pathogenic bacteria isolated from
hospitalized patients with hematologic tumors in the hospital from July 2021 to June 2022, and the results were analyzed. Results: A
total of 86 patients with hematologic tumors were collected, and 124 strains of pathogenic bacteria were detected. Among them, 72
strains were Gram-negative bacteria (58.06%), 49 strains were Gram-positive bacteria(39.52%), and 3 strains were fungi(2.42%).
The most frequently isolated pathogenic bacteria were Escherichia coli with 28 strains(22.58%). The results of drug sensitivity showed
that E. coli had a low resistance rate to carbapenems, while Staphylococcus aureus had a high resistance rate to penicillin and
ampicillin. Conclusion: In the hospitalized patients with hematologic tumors from July 2021 to June 2022, Gram-negative bacteria
were the main isolated pathogenic bacteria, and E. coli accounted for the largest proportion. The drug resistance of pathogenic bacteria
was complex and severe. In order to ensure timely and accurate antimicrobial treatment and improve clinical efficacy, drug-sensitive
detection of pathogenic bacteria in patients should be maintained in clinical practice.

Key words: hematologic tumor, pathogenic bacteria, drug resistance

CLC Number: